|
|
Epivir (3TC, Lamivudine)
| Brand Name: |
Epivir |
| Generic Name: |
Lamivudine, 3TC |
| Adult Single Dose: |
One 150-mg tablet (twice a day) OR one 300-mg tablet (once a day) |
| Food & Liquid Restrictions: |
None |
| Drug Class: |
NRTI |
The Basics
- An Overview of Epivir (3TC, Lamivudine) (Regularly Updated)
To read PDF, click here
From U.S. National Institutes of Health
- Lamivudine (Epivir) (February 8, 2008)
To read PDF, click here
From AIDS InfoNet
- Epivir (Lamivudine, 3TC) (January/February 2008)
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Epivir (Lamivudine, 3TC) (September 28, 2007)
Basic information on dosing schedules and side effects.
From U.S. Department of Veterans Affairs
- 3TC (Epivir, Lamivudine) (October 26, 2006)
From AIDS Treatment Data Network
- Patient Information About Epivir (3TC, Lamivudine) (PDF) (October 2006)
From GlaxoSmithKline
- Epivir (Lamivudine) (September 6, 2006)
To read PDF, click here
From The Center for AIDS
- Drug Interactions: Lamivudine (August 2004)
From Project Inform
News
- Epivir Tablets for Pediatric Dosing (February 7, 2008)
From U.S. Food and Drug Administration
- Two New Fixed-Dose Combinations Approved (August 2, 2004)
From U.S. Food and Drug Administration
- WHO Approves New Generic Lamivudine, Fluconazole Pills (July 14, 2004)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- WHO Removes Cipla's Lamivudine, Zidovudine Generics From Approved Drug List (June 16, 2004)
In Kaiser Daily HIV/AIDS Report, from Henry J. Kaiser Family Foundation
- Drug Development News: Fixed-Dose Combinations (May/June 2004)
The Food and Drug Administration's fast-track approval process for fixed-dose combinations is about to bear fruit.
In GMHC Treatment Issues, from Gay Men's Health Crisis
- Initial Therapy With d4T or 3TC Appears to Confer Survival Benefit (April 1998)
In HIV Newsline, from San Francisco General Hospital
Research
- Emtricitabine and Lamivudine May Be Similar, but Their Resistance Profiles Differ in Important Ways (February 6, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections
- HIV JournalView: Study Ties Insulin Resistance to NRTIs, Not PIs (September 2005)
d4T and 3TC are associated with insulin resistance and high insulin levels; indinavir is associated only with elevated insulin levels; and no link to insulin abnormalities is found for AZT or ddI.
From The Body PRO
- Lamivudine Monotherapy Better Than Treatment Interruption in Rescue Patients With M184V (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Adverse Event Risk on Abacavir + Lamivudine Is Not Higher for Patients Coinfected With Hepatitis B and/or Hepatitis C (July 26, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment
- Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from The Body PRO
- Fixed-Dose Pill of Abacavir/Lamivudine Taken Once a Day Is Comparable to Twice-a-Day Abacavir + Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- No Difference Seen in Resistance Profiles of Emtricitabine and Lamivudine (February 25, 2005)
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO
- Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO
- Virologic Failure Analyzed in a Trial of Once-Daily Versus Twice-Daily Abacavir/3TC Regimens (February 9, 2004)
In The 11th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care
- Gilead Warns Against Use of Triple-NRTI Regimen 3TC, ddI, Tenofovir (October 14, 2003)
To read PDF, click here
From U.S. Food and Drug Administration
- Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- A Comparison of AZT/3TC vs. d4T/ddI, Plus Efavirenz, Nevirapine or Indinavir/Ritonavir (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Emergence of Resistance-Associated Mutations Over 96 Weeks in Patients Initiating ABC/3TC + d4T, EFV or APV/r (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- FTC Compares Well to 3TC in Triple-NRTI Regimens (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- FTC Similar in Most Ways to 3TC (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO
- Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network
- Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration
- Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Separated at Birth: 3TC and FTC (July 2003)
A quick comparison of molecular structures.
In TAGline, from Treatment Action Group
- Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prospective Study of Regional Body Composition in Antiretroviral-Naive Subjects Randomized to Receive Zidovudine + Lamivudine or Didanosine + Stavudine Combined With Nelfinavir, Efavirenz or Both: A5005s, a Substudy of ACTG 384 (September 25, 2002)
In 4th International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, from The Body PRO
- Thai Hospital Claims Reduced Mother-Baby Transmission (July 30, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Durability and Tolerability of the Triple NRTI Regimen Abacavir/Zidovudine/Lamivudine Based on Therapy Changes in Antiretroviral Therapy-Naive Patients in the Frankfurt HIV Cohort (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- High Incidence of Primary NNRTI Mutations and M184V in Isolates From Therapy-Experienced Adults Entering the ZORRO Trial (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Zidovudine and Lamivudine Seminal Plasma: Blood Plasma Concentration Ratios Do Not Predict Total SP Exposure (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO
- Breastfeeding Wrecks Short Course Anti-HIV Treatment for Babies (April 10, 2002)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- Studies Examine Switching Off d4T to Reverse Lipoatrophy (February 26, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Prospective Study of Hyperlipidemia in ART-Naive Subjects Taking Combivir/Abacavir/Nelfinavir, or Stavudine/Lamivudine/NFV (ESS40002) (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Comparative Results (Phase II 48-Week): BMS-232632, Stavudine, Lamivudine as HAART for Treatment-Naive HIV-Positive Patients (AI424-008) (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO
- Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO
- Prevalence and Predictive Value of Intermittent Viremia With Combination HIV Therapy (July 23, 2001)
In CDC HIV/Hepatitis/STD/TB Prevention News Update, from U.S. Centers for Disease Control and Prevention
- A Randomized Open Label Study to Investigate Abacavir and Lamivudine as Once-Daily Components of a Triple-Combination Regimen (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Comparison of the Plasma Pharmacokinetics of Lamivudine During Twice-Daily and Once-Daily Dosing in HIV-1 Infected Individuals (July 9, 2001)
In The 1st International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO
- Efficacy and Safety of Switch to 3TC 300 mg QD vs. Continued 3TC 150 mg BID in Subjects with Virologic Suppression on Stable 3TC/d4T/PI Therapy (COLA4005): Final 24-Week Results (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Evaluation of Novel Combination of Abacavir, Lamivudine and Efavirenz (July 12, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Once-a-Day Therapy for HIV Infection (July 11, 2000)
In The XIII International AIDS Conference, from The Body PRO
- Characterization of Lamivudine Pharmacokinetics in Cerebrospinal Fluid and Plasma by Ultra-Intensive Sampling (November 19, 1999)
In The 37th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Efavirenz + Zidovudine + Lamivudine Provides Superior Long-Term HIV-RNA Suppression, Antiretroviral Activity and Tolerability Versus Indinavir + ZDV + 3TC: Results of Study 006 at 72 Weeks (Initial Cohort) (November 19, 1999)
In The 37th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO
- Therapy with d4T plus 3TC Produces Sustained Undetectable Levels of Plasma HIV RNA in Patients Treated with Reverse Transcriptase Inhibitors for 10 Years (February 4, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Antiviral Activity and Acceptance of Two Different Triple Combinations (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- Combination Therapy With AZT + 3TC + Indinavir vs. d4T + 3TC + Indinavir in Pretreated Patients With Less Than 200 CD4/mm3 (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- d4T+3TC Versus AZT+3TC: Shattering the Synergy Story (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
- The START Trials (February 3, 1998)
In The 5th Conference on Retroviruses and Opportunistic Infections, from The Body PRO
|
Advertisement
|
